Monday, May 6, 2024
spot_img

Indian American Researcher backs T-cell Covid Vaccine

The current Covid vaccines are designed to trigger an antibody response to the SARS-CoV-2 spike protein, which is vulnerable to mutations that could make the vaccine less effective over time. Focusing on the T-cell instead, Pennsylvania State University researchers in the US partnered with Evaxion Biotech on a study that was the first to demonstrate the effectiveness of an AI-generated vaccine in a live viral challenge model

PRAVASISAMWAD.COM

A T-cell-based Covid vaccine may last longer than the current jabs, providing long-lasting immunity against future emerging variants, and could be used as a model for other seasonal viral diseases like the flu, Indian American researcher Girish Kirimanjeswara, associate professor of veterinary and biomedical sciences, Penn State has revealed.

The current Covid vaccines are designed to trigger an antibody response to the SARS-CoV-2 spike protein, which is vulnerable to mutations that could make the vaccine less effective over time. Focusing on the T-cell instead, Pennsylvania State University researchers in the US partnered with Evaxion Biotech on a study that was the first to demonstrate the effectiveness of an AI-generated vaccine in a live viral challenge model.

  • “Our vaccine was extremely effective at preventing severe Covid-19 in mice, and it can be easily scaled up to start testing it in humans, as well.”

  • The research also paves the way for the potential rapid design of novel Tcell vaccines against emerging and seasonal viral diseases, like influenza.

  • According to Kirimanjeswara, the spike protein of the SARS-CoV-2 virus is under heavy selection pressure, which can result in mutations that drive the emergence of new variants.

  • “This means that vaccine manufacturers will have to keep creating new vaccines that target new variants, and people have to keep getting these new vaccines.”

  • The virus would have to undergo too many mutations to be able to escape this T-cell-mediated immunity, so that is one advantage.

  • “The second advantage is that T-cell-mediated immunity is usually long lasting, so you don’t need repeated booster doses,” Kirimanjeswara explained. 

In their study, the researchers challenged mice with a lethal dose of SARSCoV-2 and found that 87.5 per cent of the mice that were vaccinated with the T-cell-based vaccine survived, while only one of the control-group mice survived. Additionally, all the vaccinated mice that survived cleared the infection within 14 days post-challenge, said the study published in the journal Frontiers in Immunology.

“To our knowledge, this study is the first to show in vivo protection against severe Covid-19 by an AI-designed T-cell vaccine,” said Kirimanjeswara.

“Our vaccine was extremely effective at preventing severe Covid-19 in mice, and it can be easily scaled up to start testing it in humans, as well,” he added. The research also paves the way for the potential rapid design of novel Tcell vaccines against emerging and seasonal viral diseases, like influenza. According to Kirimanjeswara, the spike protein of the SARS-CoV-2 virus is under heavy selection pressure, which can result in mutations that drive the emergence of new variants. “This means that vaccine manufacturers will have to keep creating new vaccines that target new variants, and people have to keep getting these new vaccines,” he noted. The virus would have to undergo too many mutations to be able to escape this T-cell-mediated immunity, so that is one advantage. “The second advantage is that T-cell-mediated immunity is usually long lasting, so you don’t need repeated booster doses,” Kirimanjeswara explained.

*********************************************************

Readers

These are extraordinary times. All of us have to rely on high-impact, trustworthy journalism. And this is especially true of the Indian Diaspora. Members of the Indian community overseas cannot be fed with inaccurate news.

Pravasi Samwad is a venture that has no shareholders. It is the result of an impassioned initiative of a handful of Indian journalists spread around the world.  We have taken the small step forward with the pledge to provide news with accuracy, free from political and commercial influence. Our aim is to keep you, our readers, informed about developments at ‘home’ and across the world that affect you.

Please help us to keep our journalism independent and free.

In these difficult times, to run a news website requires finances. While every contribution, big or small, will makes a difference, we request our readers to put us in touch with advertisers worldwide. It will be a great help.

For more information: pravasisamwad00@gmail.com

Tirthankar Ghosh
Tirthankar Ghosh
Tirthankar Ghosh is a senior journalist and presently Managing Editor, Newsline Publications. He has also been writing for well over 15 years for the New York-based Air Cargo News Flying Typers.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisement -

EDITOR'S CHOICE

Register Here to Nominate